Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Pier Paolo Olimpieri
How Many Chronic Myeloid Leukemia Patients Who Started a Frontline Second‐generation Tyrosine Kinase Inhibitor Have to Switch to a Second‐line Treatment? A Retrospective Analysis From the Monitoring Registries of the Italian Medicines Agency (AIFA)
Cancer Medicine
Cancer Research
Nuclear Medicine
Radiology
Imaging
Oncology
Related publications
Use of Second Generation Tyrosine Kinase Inhibitors for Second-Line Treatment of Chronic Myeloid Leukemia After Imatinib Failure
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
Oncology
Hematology
Arterial Events in Patients With Chronic Myeloid Leukemia Receiving Treatment With Second Generation Tyrosine Kinase Inhibitors
Klinicheskaya Onkogematologiya/Clinical Oncohematology
Oncology
Hematology
The Management of Chronic Myeloid Leukemia in the Era of Second Generation Tyrosine Kinase Inhibitors
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
Oncology
Hematology
Managing Chronic Myeloid Leukemia Patients Intolerant to Tyrosine Kinase Inhibitor Therapy
Blood Cancer Journal
Oncology
Hematology
Use of Second- And Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Tyrosine Kinase Inhibitor Sequencing in Patients With Chronic Myeloid Leukemia
Oncology and Therapy
Oncology
Long-Term Outcomes in the Second-Line Treatment of Chronic Myeloid Leukemia
Cancer
Cancer Research
Oncology
Discovering Gene Expression Signatures Responding to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia
BMC Medical Genomics
Genetics
Thyroid Dysfunction Caused by Second-Generation Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Thyroid
Medicine
Endocrinology
Metabolism
Diabetes
